Abstract: Methods of treating cancer and autoimmune and inflammatory diseases are provided.

Abstract: Methods of treating cancer and autoimmune and inflammatory diseases are provided.

Abstract: Methods of treating cancer and autoimmune and inflammatory diseases are provided.

Abstract: Methods of treating cancer and autoimmune and inflammatory diseases are provided.

Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.

Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.

Abstract: The present invention relates to a gene and gene product, SGA-1M that is differentially expressed in cancer tissues and cell lines. Suppression Subtractive Hybridization and microarray screening were used to screen for differential expression of SGA-1M in cancer tissues and cell lines. Expression analysis has demonstrated overexpression of SGA-1M in breast cancer tissue and breast cancer derived cell lines, in ovarian cancer, skin cancer, a cancer of the lymphoid system, thyroid cancer, pancreatic cancer, stomach cancer, and lung cancer. The gene is expressed as a 1.95 kb mRNA. The full length cDNA comprises two open reading frames encoding polypeptides of 221 and 75 amino acids, respectively. Monitoring expression levels of SGA-1M is useful for the diagnosis and prognosis of cancer as well as for evaluating the risk of developing certain types of cancers and the risk of metastasis of cancer. Reagents that target SGA-1M are useful for the treatment of cancer.

Abstract: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.

Abstract: The present invention relates to nucleic and amino acid sequences of SGA-56M and variants thereof. An exemplary variant of SGA-56M is SGA-56Mv. SGA-56M and SGA-56Mv are differentially expressed in cancer tissues and transformed cell lines. In particular, these genes are expressed at elevated levels in breast cancer and lung cancer tissues and cell lines. The present invention is also directed to methods for diagnosing a cancer in a subject, determining the prognosis of a cancer patient, and/or monitoring the efficacy of a treatment regimen for a cancer patient. The present invention further provides methods for screening and identifying modulators (e.g., antagonists or agonists) of SGA-56M and/or SGA-56Mv expression and/or activity. Antagonists identified using the methods of the invention are useful for the treatment of cancer patients.

Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.

Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies-of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Abstract: A coating apparatus for applying a coating liquid to a printing substrate. The coating apparatus has a rotatable first roll and a rotatable second roll, each having a surface energy. The second roll is positioned adjacent to the first roll and defines with the first roll a first nip through which the printing substrate passes A metering device is provided for applying a substantially uniform layer of coating liquid onto the second roll. The second roll in turn transfers the coating liquid to the printing substrate. The surface energy of the second roll is greater than the surface energy of the coating liquid. In one embodiment, the metering device includes a rotatable third roll and a doctor blade contacting the third roll, each having a surface energy. The surface energy of at least a portion of either or both the third roll and doctor blade is less than the surface energy of the coating liquid.

Abstract: The present invention relates to methods and compositions for the treatment of CD20-expressing cancers and immune disorders involving CD20-expressing cells. The present methods comprise administering to a subject an anti CD20 antibody-drug conjugate that has a high potency and/or is capable of internalizing into CD20-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention yet further provides methods of and compositions relating to combination therapy of cancer and immune disorders involving CD20-expressing cells using the anti-CD20 antibody-drug conjugates of the invention.

Abstract: The present invention relates to methods for the treatment of immunological disorders other than cancer, comprising administering proteins characterized by their ability to bind to CD30 and exert a cytostatic or cytotoxic effect on an activated lymphocyte. Such proteins include monoclonal antibodies AC10 and IleFi1. AC10 and HeFi-1 derivatives, and antibodies that compete with AC10 and HeFi-1 for binding to CD30. Other such proteins include multivalent anti-CD30 antibodies and anti-CD30 antibodies conjugated to cytotoxic agents. Treatment modalities with antibodies of the invention are also provided.

Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Abstract: An ink jet printer jets ink onto a section of a front side of a print medium. The ink jet printer includes an ink jetting printhead facing the front side of the print medium. A media support apparatus opposes the printhead. The media support apparatus includes a substantially flexible body having an outer surface engaging a back side of the print medium such that the section of the print medium receiving the ink is substantially flat. A substantially rigid elongate element engages the body and has a length direction substantially perpendicular to a feed direction of the print medium. The elongate element provides at least a portion of the outer surface of the body with a predetermined degree of straightness.

Abstract: An imaging apparatus provides a machine frame including a first side frame and a second side frame. A first plurality of platen mounting members is provided which are spaced apart and extend from the first side frame. A second plurality of platen mounting members is provided which are spaced apart and extend from the second side frame. A platen is positioned to extend between the first side frame and the second side frame. The platen has a first end including a first plurality of engagement members and has a second end including a second plurality of engagement members. A biasing assembly is coupled to the machine frame, wherein the biasing assembly applies a biasing force to the platen to move the first plurality of engagement members into respective engagement with the first plurality of platen mounting members and to move the second plurality of engagement members into respective engagement with the second plurality of platen mounting members.